Efficacy of moxibustion for pre- or stage I hypertension: study protocol for a pilot randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2012-10, Vol.13 (1), p.188-188, Article 188
• Main Authors: Shin, Kyung-Min, Park, Ji-Eun, Liu, Yan, Jung, Hee-Jung, Jung, So-Young, Lee, Min-Hee, Kang, Kyung-Won, Yook, Tae-Han, Choi, Sun-Mi
• Format: Article
• Language: English
• Subjects: Acupuncture; Adult; Aged; Analysis; Blood pressure; Cardiovascular disease; Cerebrovascular disease; Clinical trials; Consent; Diabetes; Drug therapy; Female; Follow-Up Studies; Heart attacks; Heart beat; Hospitals; Humans; Hypertension; Hypertension - therapy; Infectious diseases; Kidney diseases; Liver diseases; Male; Medicine; Middle Aged; Moxibustion; Moxibustion - methods; Nervous system; Pilot Projects; Pregnancy; Prehypertension; Prehypertension - therapy; Republic of Korea; Research Design; Risk factors; Steroids; Study Protocol; Surveys and Questionnaires; Thyroid gland; Tuberculosis
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/1745-6215-13-188

Hypertension is a risk factor for cardiovascular disease, and the prevalence of hypertension tends to increase with age. Current treatments for hypertension have adverse side effects and poor adherence. The purpose of this study is to evaluate the effects of moxibustion on blood pressure in individuals with pre- or stage I hypertension. Forty-five subjects with pre- or stage I hypertension will be randomized into three groups: treatment group A (2 times/week), treatment group B (3 times/week), and the control group (non-treated group). The inclusion criteria will be as follows: (1) aged between 19 and 65 years; (2) prehypertension or stage I hypertension (JNC 7, Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure); (3) the participants are volunteers and written consent obtained.The participants in the treatment group A will undergo indirect moxibustion 2 times per week for 4 weeks, and the participants in the treatment group B will undergo indirect moxibustion 3 times per week for 4 weeks. The participants in the control group (non-treated group) will maintain their current lifestyle, including diet and exercise. The use of antihypertensive medication is not permitted. The primary endpoint will be a change in patient blood pressure. The secondary endpoints will be the body mass index, lipid profile, EuroQol and Heart Rate Variability. The data will be analyzed with the Student's t-test and analysis of variance (ANOVA) (p < 0.05). The results of this study will help to establish the optimal approach for the care of adults with pre- or stage I hypertension. Clinical Research Information Service KCT0000469.